These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 15185230)

  • 1. Restored immune response to an MHC-II-Restricted antigen in tumor-bearing hosts after elimination of regulatory T cells.
    Nicholl M; Lodge A; Brown I; Sugg SL; Shilyansky J
    J Pediatr Surg; 2004 Jun; 39(6):941-6; discussion 941-6. PubMed ID: 15185230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demonstration of strong enterobacterial reactivity of CD4+CD25- T cells from conventional and germ-free mice which is counter-regulated by CD4+CD25+ T cells.
    Gad M; Pedersen AE; Kristensen NN; Claesson MH
    Eur J Immunol; 2004 Mar; 34(3):695-704. PubMed ID: 14991599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.
    Casares N; Arribillaga L; Sarobe P; Dotor J; Lopez-Diaz de Cerio A; Melero I; Prieto J; Borrás-Cuesta F; Lasarte JJ
    J Immunol; 2003 Dec; 171(11):5931-9. PubMed ID: 14634104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
    Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
    Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complementary role of CD4+CD25+ regulatory T cells and TGF-beta in oral tolerance.
    Chung Y; Lee SH; Kim DH; Kang CY
    J Leukoc Biol; 2005 Jun; 77(6):906-13. PubMed ID: 15758078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes.
    Tanaka H; Tanaka J; Kjaergaard J; Shu S
    J Immunother; 2002; 25(3):207-17. PubMed ID: 12000862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4+CD25+ cell depletion from the normal CD4+ T cell pool prevents tolerance toward the intestinal flora and leads to chronic colitis in immunodeficient mice.
    Veltkamp C; Ruhwald R; Giesem T; Autschbach F; Kaden I; Veltkamp R; Sartor RB; Stremmel W
    Inflamm Bowel Dis; 2006 Jun; 12(6):437-46. PubMed ID: 16775487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy.
    Peng L; Kjaergäard J; Plautz GE; Awad M; Drazba JA; Shu S; Cohen PA
    J Immunol; 2002 Nov; 169(9):4811-21. PubMed ID: 12391191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role for thymic and splenic regulatory CD4+ T cells induced by donor dendritic cells in allograft tolerance by LF15-0195 treatment.
    Chiffoleau E; Bériou G; Dutartre P; Usal C; Soulillou JP; Cuturi MC
    J Immunol; 2002 May; 168(10):5058-69. PubMed ID: 11994458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human CD25+ regulatory T cells maintain immune tolerance to nickel in healthy, nonallergic individuals.
    Cavani A; Nasorri F; Ottaviani C; Sebastiani S; De Pità O; Girolomoni G
    J Immunol; 2003 Dec; 171(11):5760-8. PubMed ID: 14634084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a CD4+CD25+ T cell subset committed in vivo to suppress antigen-specific T cell responses without additional stimulation.
    Nolte-'t Hoen EN; Wagenaar-Hilbers JP; Boot EP; Lin CH; Arkesteijn GJ; van Eden W; Taams LS; Wauben MH
    Eur J Immunol; 2004 Nov; 34(11):3016-27. PubMed ID: 15376196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules.
    Frey AB; Cestari S
    Cell Immunol; 1997 May; 178(1):79-90. PubMed ID: 9184701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion.
    Wang LX; Chen BG; Plautz GE
    J Immunol; 2002 Sep; 169(6):3314-20. PubMed ID: 12218152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M; Plautz GE; Shu S
    Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors.
    Plautz GE; Mukai S; Cohen PA; Shu S
    J Immunol; 2000 Oct; 165(7):3656-62. PubMed ID: 11034369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early events in peripheral regulatory T cell induction via the nasal mucosa.
    Unger WW; Hauet-Broere F; Jansen W; van Berkel LA; Kraal G; Samsom JN
    J Immunol; 2003 Nov; 171(9):4592-603. PubMed ID: 14568933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4+ T cells cooperate with macrophages for specific elimination of MHC class II-negative cancer cells.
    Corthay A
    Adv Exp Med Biol; 2007; 590():195-208. PubMed ID: 17191387
    [No Abstract]   [Full Text] [Related]  

  • 18. The natural immune response to inhaled soluble protein antigens involves major histocompatibility complex (MHC) class I-restricted CD8+ T cell-mediated but MHC class II-restricted CD4+ T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production.
    McMenamin C; Holt PG
    J Exp Med; 1993 Sep; 178(3):889-99. PubMed ID: 8102390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy with tumor cell lysate-pulsed CD8α+ dendritic cells modulates intra-tumor and spleen lymphocyte subpopulations.
    Azadmehr A; Pourfathollah AA; Amirghofran Z; Hassan ZM; Moazzeni SM
    Neoplasma; 2013; 60(5):525-32. PubMed ID: 23790171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased numbers and suppressive activity of regulatory CD25(+)CD4(+) T lymphocytes in the absence of CD4 engagement by MHC class II molecules.
    Shen X; Niu C; König R
    Cell Immunol; 2013 Apr; 282(2):117-28. PubMed ID: 23770721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.